Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
Thursday, July 7, 2011 - 06:00
in Health & Medicine
Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).